The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice

Nephrology Dialysis Transplantation

Volumn 30, Issue 6, 2015, Pages 969-977

  Suyama, Kazuhide ^a   Kawasaki, Yukihiko ^a   Miyazaki, Kyohei ^a   Kanno, Syuto ^a   Ono, Atsushi ^a   Ohara, Shinichiro ^a   Sato, Masatoki ^a   Hosoya, Mitsuaki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

hemolytic uremic syndrome; lipopolysaccharide; mice; recombinant human soluble thrombomodulin; verotoxin

Indexed keywords

CD31 ANTIGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; FIBRINOGEN DEGRADATION PRODUCT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN; RECOMBINANT THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; LIPOPOLYSACCHARIDE; RECOMBINANT PROTEIN; SHIGA TOXIN; THBD PROTEIN, HUMAN; THROMBOMODULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOLYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM INJURY; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; KIDNEY FAILURE; KIDNEY INJURY; MALE; MESANGIOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TYPICAL HEMOLYTIC UREMIC SYNDROME; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENZYME IMMUNOASSAY; GENETICS; HEMOLYTIC-UREMIC SYNDROME; HUMAN; KIDNEY; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISEASE MODELS, ANIMAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SHIGA TOXIN; THROMBOMODULIN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939610926     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv004     Document Type: Article

References (33)

1. Karmali MA, Petric M, Lim C et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-782
2. Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol 2011; 26: 523-533
3. Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 575-585
4. Karpman D. Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. Nephrol Dial Transplant 2012; 27: 3669-3674
5. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008; 23: 1749-1760
6. Bitzan M, Bickford BB, Foster GH. Verotoxin (shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: possible implications for the hemolytic uremic syndrome. J Am Soc Nephrol 2004; 15: 2334-2343
7. Bitzan M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int Suppl 2009; 112: S62-S66
8. Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563
9. Kielstein JT, Beutel G, Fleig S et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27: 3807-3815
10. Delmas Y, Vendrely B, Clouzeau B et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014; 29: 565-572
11. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430
12. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-357
13. Yamakawa K, Fujimi S, Mohri T et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011; 15: R123
14. Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41
15. Honda T, Ogata S, Mineo E et al. A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin α. Pediatrics 2013; 131: e928-e933
16. Kawasaki Y, Suyama K, Ono A et al. The efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome. Pediatr Int 2013; 55: e139-e142
17. Keepers TR, Psotka MA, Gross LK et al. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 2006; 17: 3404-3414
18. Ohara S, Kawasaki Y, Abe Y et al. Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome. Am J Nephrol 2012; 36: 516-523
19. Zoja C, Locatelli M, Pagani C et al. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. J Immunol 2012; 189: 3661-3668
20. Kawasaki Y, Tanji M, Takano K et al. The leukotriene B4 receptor antagonist ONO-4057 inhibits mesangioproliferative changes in anti-Thy-1 nephritis. Nephrol Dial Transplant 2005; 20: 2697-2703
21. Kato T, Sakai T, Kato M et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study. Thromb J 2013; 11: 3
22. Conway EM, Van de Wouwer M, Pollefeyt S et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196: 565-577
23. Van de Wouwer M, Conway EM. Novel functions of thrombomodulin in inflammation. Crit Care Med 2004; 32: S254-S261
24. Abeyama K, Stem DM, Ito Y et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005; 115: 1267-1274
25. Ito T, Kawahara K, Okamoto K et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008; 28: 1825-1830
26. Shi CS, Shi GY, Hsiao SM et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008; 112: 3661-3670
27. Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med 2005; 11: 475-477
28. Ozaki T, Anas C, Maruyama S et al. Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischaemic acute renal failure. Nephrol Dial Transplant 2008; 23: 110-119
29. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34: 107-125
30. Morigi M, Galbusera M, Gastoldi S et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187: 172-180
31. Tegla CA, Cudrici C, Patel S et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 2011; 51: 45-60
32. Van de Wouwer M, Plaisance S, De Vriese A et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Hoemost 2006; 4: 1813-1824
33. Taylor FB, Tesh VL, Devault L et al. Characterization of the Baboon responses to Shiga-Like Toxin. descriptive study if a new primate model of toxic responses to Stx-1. Am J Pathol 1999; 154: 1285-1299